Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
By Y. Furuta, T. Komeno, Takaaki Nakamura. Proceedings of the Japan Academy. Series B, Physical and biological sciences, 2017
956 citations recorded by the source corpus.
Favipiravir (T-705; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is an anti-viral agent that selectively and potently inhibits the RNA-dependent RNA polymerase (RdRp) of RNA viruses. Favipiravir was discovered through screening chemical library for anti-viral activity against the influenza virus by Toyama Chemical Co., Ltd. Favipiravir undergoes an intracellular phosphoribosylation to be an active form, favipiravir-RTP (favipiravir ribofuranosyl-5′-triphosphate), which is recognized as a substrate by RdRp, and inhibits the RNA polymerase activity. Since the catalytic domain of RdRp is conserved among various types of RNA viruses, this mechanism of action underpins a broader spectrum of anti-viral activities of favipiravir. Favipiravir is effective against a wide range of types and subtypes of influenza viruses, including strains resistant to existing anti-influenza drugs. Of note is that favipiravir shows anti-viral activities against other RNA viruses such as arenaviruses, bunyaviruses and filoviruses, all of which are known to cause fatal hemorrhagic fever. These unique anti-viral profiles will make favipiravir a potentially promising drug for specifically untreatable RNA viral infections.
Subfields: Epidemiology, Infectious Diseases
View Paper: https://www.semanticscholar.org/paper/30771b50bc475875491179968e988e12509a7e70
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
Citations in the corpus
- SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development (2020, background): “In this aspect, the holism-based traditional Chinese medicine especially the Chinese medical herb formulae could be considered which are proved effective in the fight against COVID-19 in China (Ang et al., Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 14 2020; Luo et al., 20”
- Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. (2020, neutral): “7) ICU: 52 (100); ARDS: 35 (67); MI: 12 (23); AKI: 15 (29); bacterial infection: 8 (15) ICU: 2 (11); ARDS: 0 (0); secondary bacterial infection: (0) ICU: 1 (8); culture-positive secondary bacterial infection: 0 (0) ICU: 55 (5); ARDS: 37 (3.”
- A Review of SARS-CoV-2 and the Ongoing Clinical Trials (2020, methodology): “Similar to remdesivir, favipiravir, developed by Toyama Chemical (division of Fujifilm, Japan), functions as an inhibitor of the RNA-dependent RNA polymerase by structurally resembling the endogenous guanine [48].”
- Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency (2020, background): “In cell culture, these inhibitors often show EC50 values in the higher micromolar range depending on the nature of the RNA virus (26, 41, 42).”
- COVID-19 and Cardiovascular Disease (2020, background): “Myocardial injury, evidenced by elevated cardiac biomarkers, was recognized among early cases in China.”
- Discovering drugs to treat coronavirus disease 2019 (COVID-19). (2020, background): “Favipiravir is converted into an active phosphoribosylated form (favipiravir-RTP) in cells and is recognized as a substrate by viral RNA polymerase, thus inhibiting RNA polymerase activity (11).”